New Parkinson's drug candidate passes first safety check in healthy volunteers
NCT ID NCT06088784
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new oral drug, ATH-399A, in 76 healthy adults to see if it is safe and how the body processes it. The goal is to gather information needed to develop a treatment for Parkinson's disease. Participants took single or multiple doses, and researchers also checked if food affected the drug. No direct benefit was expected for volunteers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Syneos Quebec Canada
Québec, QC G1P 0A2, Canada